Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
Oncotype
What is your approach to chemotherapy for a postmenopausal woman with T1c,N0,G2 IDC and oncotype of 25?
Related Questions
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
How do you assess and counsel women with chronic post-lumpectomy or mastectomy pain?
Would you discontinue or dose-reduce tamoxifen in a patient who developed hepatic steatosis?
What factors do you take into account when deciding which gene expression assay to utilize when making adjuvant treatment decisions in patients with non-metastatic breast cancer?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
Would you discontinue tamoxifen for endometrial hyperplasia without dysplasia in the adjuvant setting?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
How to treat a patient with bilateral breast cancer, HER2 positive on one side and HER2 negative on the contralateral side, particularly in regards to adjuvant CDK4/6 inhibitors vs Neratinib?
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
What are your top takeaways in Radiation Oncology from SABCS 2024?
